Last A$0.27 AUD
Change Today +0.015 / 6.00%
Volume 62.8K
GBI On Other Exchanges
Symbol
Exchange
Berlin
As of 12:51 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

genera biosystems ltd (GBI) Snapshot

Open
A$0.25
Previous Close
A$0.25
Day High
A$0.27
Day Low
A$0.25
52 Week High
06/18/14 - A$0.38
52 Week Low
10/23/13 - A$0.09
Market Cap
23.9M
Average Volume 10 Days
27.6K
EPS TTM
A$-0.03
Shares Outstanding
90.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENERA BIOSYSTEMS LTD (GBI)

Related News

No related news articles were found.

genera biosystems ltd (GBI) Related Businessweek News

No Related Businessweek News Found

genera biosystems ltd (GBI) Details

Genera Biosystems Limited develops and commercializes multiplexed molecular diagnostic tests in Australia. The company develops molecular diagnostic tests based upon its proprietary AmpaSand bead-based technology that facilitates the multiplexing of tests by identifying individual clusters of beads within a larger pool. Its products include RTIplex, a multiplexed and automated PCR based test for upper respiratory tract analytes; and PapType, a molecular diagnostic test for the simultaneous detection and genotyping of high risk and low risk types of human papillomaviruses that cause cervical cancer or genital warts. The company also develops next-generation, ultra-sensitive, and real-time detection systems. Its products are used by commercial pathology providers. The company is based in Scoresby, Australia.

genera biosystems ltd (GBI) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: --
Executive Chairman, Member of Audit & Risk Co...
Total Annual Compensation: A$5.5K
Chief Scientific Officer, Executive Director ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

genera biosystems ltd (GBI) Key Developments

Genera Biosystems Limited Appoints Richard Hannebery as CEO

Genera Biosystems Limited announced the appointment of Richard Hannebery to the position of CEO. Mr. Hannebery will formally commence in his role on 15 October, 2014 and his employment arrangements will be released to the market at that time.

Genera Biosystems Limited Enters into Strategic Commercial Collaboration Agreement with Beckman Coulter Life Sciences

Genera Biosystems Limited announced that it has entered into a Strategic Commercial Collaboration Agreement (`SCC') with Beckman Coulter Life Sciences. Under the SCC, the two companies will work closely together with the initial objective of integrating the PapType HPV assay on a Beckman Coulter flow cytometry platform. Upon completion, Genera will move to complete its 6,000 patient HPV screening study with the Wolfson Institute in London with the Beckman Coulter instrumentation. Also following successful integration of PapType, Genera will integrate its RTI-Plex and STI-Plex assays on the Beckman Coulter platform. In addition to these 3 high value molecular diagnostic (`MDx') assays both companies have agreed to explore further menu expansion of the AmpaSand platform capable of operating on Beckman Coulter's instrumentation platform.

Genera Biosystems Limited Announces Preliminary Final Earnings Results for the Year Ended June 30, 2014

Genera Biosystems Limited announced preliminary final earnings results for the year ended June 30, 2014. The company reported revenue of AUD 206,893 compared with AUD 67,084 a year ago. Loss before income tax was AUD 2,913,524 compared with AUD 2,605,324 a year ago. Net loss for the year was AUD 2,461,958 compared with AUD 2,262,872 a year ago. Basic and diluted loss per share was 2.888 cents compared with 2.584 cents a year ago. Net cash flow from operating activities was AUD 848,398 compared with AUD 1,478,165 a year ago. Payments for purchase of intangibles were AUD 229,678 compared with AUD 195,296 a year ago. Payments for purchase of plant and equipment were AUD 700 compared with AUD 248,536 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBI:AU A$0.27 AUD +0.015

GBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GBI.
View Industry Companies
 

Industry Analysis

GBI

Industry Average

Valuation GBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 102.5x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 99.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENERA BIOSYSTEMS LTD, please visit www.generabiosystems.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.